Dopaminergic medication boosts action–effect binding in Parkinson's disease
Authors:
- James W. MooreJMJames W. Moore
- Susanne A. SchneiderSSSusanne A. Schneider
- Petra SchwingenschuhPSPetra Schwingenschuh
- Giovanna MorettoGMGiovanna Moretto
- Kailash P. BhatiaKBKailash P. Bhatia
- Patrick HaggardPHPatrick Haggard
- 1 March 2010
- journal article
- research article
- Published by Elsevier in Neuropsychologia
- Vol. 48 (4) , 1125-1132
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Ketamine “unlocks” the reduced clock-speed effects of cocaine following extended training: Evidence for dopamine–glutamate interactions in timing and time perceptionNeurobiology of Learning and Memory, 2007
- Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's diseaseNeuroscience & Biobehavioral Reviews, 2006
- What makes us tick? Functional and neural mechanisms of interval timingNature Reviews Neuroscience, 2005
- Enhanced or Impaired Cognitive Function in Parkinson's Disease as a Function of Dopaminergic Medication and Task DemandsCerebral Cortex, 2001
- What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?Brain Research Reviews, 1998
- Does parkinsonian action tremor contribute to muscle weakness in Parkinson's disease?Brain, 1997
- Strength in Parkinson's disease: Relationshp to rate of force generation and clinical statusAnnals of Neurology, 1996
- TEMPORAL DISCRIMINATION IS ABNORMAL IN PARKINSON'S DISEASEBrain, 1992
- Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and CortexAnnual Review of Neuroscience, 1986
- INITIATION AND EXECUTION OF PREDICTABLE AND UNPREDICTABLE MOVEMENTS IN PARKINSON'S DISEASEBrain, 1984